In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on NeoGenomics (NEO – Research Report). The company’s shares ...

NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a shocking sell-off after Chief Executive Chris Smith announced his retirement on Monday.

While not a mind-blowing move, it is good to see that the NeoGenomics, Inc. (NASDAQ:NEO) share price has gained 10% in the last three months. But don't envy holders -- looking back over 5 years ...

Shares of NeoGenomics tumbled after the oncology testing-services company said its chief executive, Chris Smith, will retire April 1. The stock fell 20%, to $14.91, in afternoon trading Friday.

Needham analyst Michael Matson reiterated a Buy rating on NeoGenomics (NEO – Research Report) today and set a price target of $19.00. Discover outperforming stocks and invest smarter with Top ...

On January 10, 2025, NeoGenomics, Inc. (the “Company”) announced that Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will ...

Ratings for NeoGenomics (NASDAQ:NEO) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

PacBio总裁兼首席执行官Christian Henry表示："我们非常高兴欢迎Chris加入PacBio董事会。他在临床诊断和基因组学方面的深厚专业知识，将在我们继续拓展临床基因组市场时发挥宝贵作用。" 与此同时，David Meline自今日起辞去PacBio董事会职务。Meline自2023年起担任董事会成员，公司对他为公司战略方向所做的贡献表示认可。